Search -

Displaying 1 - 11 of 11

Sort: Relevancy | Date

Presentation TCT 2019

Role of New-Gen DES in Patients at HBR: Does Stent Type Matter?

Presenter: Ajay Kirtane

September 28, 2019

Presentation TCT 2019

STOPDAPT-2 HBR: 1-Year Outcomes From a Randomized Trial of Clopidogrel Monotherapy vs. DAPT Beginning 1 Month After PCI in Patients at High Bleeding Risk

Presenter: Hirotoshi Watanabe

September 28, 2019

Presentation TCT 2019

Defining High Bleeding Risk: HBR ARC

Presenter: Philip Urban

September 27, 2019

Presentation TCT 2019

Clinical Trial Design in HBR Patients: Should Risk Scores Be Incoporated?

Presenter: Davide Capodanno

September 27, 2019

Presentation TCT 2019

Idenifying the High Bleeding Risk Patient: The ARC HBR Definitions

Presenter: Philip Urban

September 27, 2019

Presentation TCT 2019

Study Design Considerations for HBR Patients in Japan

Presenter: Yasuko Nakamura

September 26, 2019

Presentation TCT 2019

Study Design Considerations for HBR Patients and DES Platforms: FDA View

Presenter: Adrian Magee

September 26, 2019

Presentation TCT 2019

PCI for HBD Patients in Japan: Current Clinical Treatment and Post-Market Treatment

Presenter: Junya Ako

September 26, 2019

Presentation TCT 2019

ARC Definition of High Bleeding Risk: Global Impact on HBR PCI Clinical Studies?

Presenter: Hans-Peter Stoll

September 26, 2019

Presentation CIT 2019

HBR studies and cases examples of HBR patients

Presenter: MC Morice

March 28, 2019

Presentation CIT 2019

The landscape of Ongoing HBR Clinical Trials & an Introduction to HBR-ARC Initiative

Presenter: Roxana Mehran

March 28, 2019

Advertisement

Role of New-Gen DES in Patients at HBR: Does Stent Type Matter?

STOPDAPT-2 HBR: 1-Year Outcomes From a Randomized Trial of Clopidogrel Monotherapy vs. DAPT Beginning 1 Month After PCI in Patients at High Bleeding Risk

Defining High Bleeding Risk: HBR ARC

Clinical Trial Design in HBR Patients: Should Risk Scores Be Incoporated?

Idenifying the High Bleeding Risk Patient: The ARC HBR Definitions

Study Design Considerations for HBR Patients in Japan

Study Design Considerations for HBR Patients and DES Platforms: FDA View

PCI for HBD Patients in Japan: Current Clinical Treatment and Post-Market Treatment

ARC Definition of High Bleeding Risk: Global Impact on HBR PCI Clinical Studies?

HBR studies and cases examples of HBR patients

The landscape of Ongoing HBR Clinical Trials & an Introduction to HBR-ARC Initiative

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content